Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15095887 | 0.71 | CHRM2 (0.46) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL12700286 | 0.71 | CHRM2 (0.46) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL8515490 | 0.71 | CHRM2 (0.46) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL9297048 | 0.70 | — | — | |
| SCHEMBL9520004 | 0.70 | ALDH1A1 (0.32) | — | |
| SCHEMBL15345987 | 0.70 | — | — | |
| SCHEMBL22788167 | 0.68 | — | — | |
| SCHEMBL249430 | 0.68 | CHRM2 (0.34) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17242630 | 0.67 | — | — | |
| SCHEMBL14635932 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3268372-B9 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | 4SC AG (DE) | 2021-03-31 | — | — | EP | disclosed |
| CN-107548397-B | Kv1.3 inhibitors and medical uses thereof | 4SC股份公司 | 2020-12-29 | — | — | CN | disclosed |
| US-20200377514-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | 4SC AG (DE) | 2020-12-03 | — | — | US | disclosed |
| US-10822345-B2 | KV1.3 inhibitors and their medical application | 4SC AG (DE) | 2020-11-03 | — | — | US | disclosed |
| US-20200339592-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | 4SC AG (DE) | 2020-10-29 | — | — | US | disclosed |
| US-10723743-B2 | Kv1.3 inhibitors and their medical application | 4SC AG (DE) | 2020-07-28 | — | — | US | disclosed |
| EP-3268372-B1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | 4SC AG (DE) | 2020-07-01 | — | — | EP | disclosed |
| CN-107548396-B | Kv1.3 inhibitors and medical uses thereof | 4SC股份公司 | 2020-04-28 | — | — | CN | disclosed |
| US-20190352308-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATIONS | 4SC AG (DE) | 2019-11-21 | — | — | US | disclosed |
| EP-3268374-B1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | 4SC AG (DE) | 2019-09-25 | — | — | EP | disclosed |
| WO-2015170081-A1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2015-11-12 | — | — | WO | disclosed |
| US-20150225389-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | eXIthera Pharmaceuticals Inc. (US) | 2015-08-13 | — | — | US | disclosed |
| US-8841334-B2 | Compounds as cannabinoid receptor ligands and uses thereof | ABBVIE INC. (US) | 2014-09-23 | — | — | US | disclosed |
| EP-2222165-B1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2013-07-31 | — | — | EP | disclosed |
| US-8329691-B2 | Amide compounds and use of the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100324010-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-23 | — | — | US | disclosed |
| EP-2222165-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20100093814-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2009067613-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | WO | disclosed |
| EP-0627411-A1 | Azine-substituted phenylacetic acid derivatives and fungicides containing them | BASF Aktiengesellschaft (DE) | 1994-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324010-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | REN, ACE, AGT | CHRM2 3801/4885CHRM4 4262/4885CHRM5 3659/4885 |
| US-20190352308-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATIONS | KCNA3, KCNN3, KCNH3 | CHRM2 248/4885CHRM4 454/4885CHRM5 287/4885 |
| US-20100093814-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | CHRM2 64/4885CHRM4 148/4885CHRM5 120/4885 |
| US-20200339592-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | KCNA3, KCNN3, KCNK3 | CHRM2 1240/4885CHRM4 1522/4885CHRM5 1162/4885 |
| US-10723743-B2 | Kv1.3 inhibitors and their medical application | KCNA3, KCNN3, KCNK3 | CHRM2 1240/4885CHRM4 1522/4885CHRM5 1162/4885 |
| US-20150225389-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLKB1, KLK2 | CHRM2 4814/4885CHRM4 4734/4885CHRM5 4646/4885 |
| US-10822345-B2 | KV1.3 inhibitors and their medical application | KCNA3, KCNN3, KCNK3 | CHRM2 1240/4885CHRM4 1522/4885CHRM5 1162/4885 |
| US-20200377514-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | KCNN3, KCNN2, KCNA3 | CHRM2 459/4885CHRM4 608/4885CHRM5 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.